Published in Arch Neurol on September 01, 2009
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol (2014) 2.37
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica. Nat Rev Neurol (2011) 1.30
AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm (2014) 1.17
Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun (2012) 1.16
Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol (2010) 1.10
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 1.09
Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation (2010) 0.98
Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One (2013) 0.95
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One (2013) 0.94
Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91
White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLoS One (2012) 0.87
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One (2012) 0.85
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Illuminating neuromyelitis optica pathogenesis. Proc Natl Acad Sci U S A (2012) 0.80
Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurol (2013) 0.79
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Ann Lab Med (2012) 0.78
An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurol (2014) 0.77
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77
Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis. J Neurol (2015) 0.76
Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci (2015) 0.75
Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients. Neural Regen Res (2013) 0.75
Neuromyelitis optica spectrum disease with positive autoimmune indices: a case report and review of the literature. Case Rep Med (2011) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res (2005) 2.16
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02
Do not treat from CIS onset: evaluate disease course and prognosis first--yes. Mult Scler (2012) 2.01
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85